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Hypoxia inducible transcription factors (HIFs) activate diverse
pathways that regulate cellular metabolism, angiogenesis, prolif-
eration, and migration, enabling a cell to respond to a low oxygen
or hypoxic environment. HIFs are regulated by oxygen-depen-
dent and independent signals including: mitochondrial dysfunc-
tion, reactive oxygen species, endoplasmic reticular stress, and
viral infection. HIFs have been reported to play a role in the path-
ogenesis of liver disease of diverse aetiologies. This review
explores the impact of HIFs on hepatocellular biology and inﬂam-
matory responses, highlighting the therapeutic potential of tar-
geting HIFs for an array of liver pathologies.
 2014 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver. Open access under 
CC BY-NC-ND license.Introduction
Oxygen is vital for all living cells and transport around the body by
the vasculature is regulated by the metabolic requirements and
functional status of the tissue or organ [1]. The liver has a unique
anatomical and functional role that affects its physiology and oxy-
gen homeostasis [2]: receiving highly oxygenated blood via the
hepatic artery and oxygen-depleted blood in the hepatic portal
vein. This directional blood ﬂow towards the central vein of theJournal of Hepatology 20
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lysophosphatidic acid.lobule creates a physiological oxygen gradient, resulting in oxy-
gen pressure (pO2) of 60–65 mmHg (8%) in the periportal area
to 30–35 mmHg (4%) in perivenous areas of the parenchyma
[3,4]. The resulting oxygen gradient associateswith liver zonation,
a phenomenon where hepatocytes show distinct functional and
structural heterogeneity across the parenchyma (Fig. 1) [5–7].
Deﬁning relative terms such as ‘normoxia’ and ‘hypoxia’ depends
on the normal oxygen tension to which an organ is exposed. It is
important to note that, despite the variable oxygen tensions in the
liver, a hypoxic response is not observed in the normal healthy
liver [8,9]. However, modest changes in oxygen tension that occur
during viral hepatitis, metabolic disorders, steatohepatitis,
inﬂammation and carcinogenesis are sufﬁcient to promote a hyp-
oxic response that stabilizes HIFs [3,10–12].
Key Points
• Hypoxia inducible factors (HIFs) regulate the 
transcription of a wide range of genes involved in 
cellular metabolism, inflammation, angiogenesis and 
proliferation
• Low oxygen tension, inflammation and viral infection 
regulate HIF expression and associated transcriptional 
activity and are implicated in several liver diseases, 
including metabolic disorders, steatohepatitis, viral 
hepatitis and hepatocellular carcinoma 
• Targeting HIFs has therapeutic potential for treating 
inflammatory liver pathologies 
Oxygen-dependent regulation of HIFsCells adapt to low oxygen through a concerted transcriptional
response [13,14] regulated by HIFs, a group of proteins belonging
to the PAS family (period circadian protein-aryl hydrocarbon
receptor nuclear translocator-single minded protein) [15]. HIFs
regulate numerous signalling events by binding speciﬁc DNA
sequences known as hypoxia responsive elements (HREs) in tar-
get genes, resulting in their increased or decreased transcription
[15,16]. There are three HIF transcription factors (HIF-1, HIF-2,
and HIF-3) that act as heterodimers comprising an alpha and beta14 vol. 61 j 1397–1406
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Fig. 1. Structural organization of the liver. (A) Haematoxylin and Eosin staining of the liver lobule which is divided into 3 zones and extends from the portal triad (hepatic
artery, portal vein and bile duct) to the central hepatic vein. (B) Schematic shows parenchymal (hepatocytes) and non-parenchymal cells (liver sinusoidal endothelial cells
[LSECs], hepatic stellate cells [HSCs] and Kupffer cells). Blood enters the liver via the portal artery and vein (zone 1/periportal) and traverses the liver lobule via the
sinusoids, incoming blood is rich in oxygen and nutrients, which depletes as the blood travels to zone 3 or the pericentral region. Arrows (red to blue) depict the oxygen
gradient across the lobule. The black arrow shows the direction of the bile ﬂow.
Reviewsubunit. The alpha subunit is regulated via oxygen-induced pro-
teolytic degradation, whereas the beta subunit is constitutively
expressed. Although stable under hypoxia, under ‘normal’ oxygen
tensions HIF-a subunits are rapidly degraded by the hydroxyl-
ation of target prolyl residues by prolyl hydroxylase domain-con-
taining proteins (PHD1–3) [17,18]. Liver speciﬁc PHD2 deletion
results in stable HIF-1a expression, whereas deleting PHD3 stabi-
lizes HIF-2a, highlighting differences in HIF-regulation. Hydroxy-
prolyl residues are recognised by the von Hippel-Lindau (pVHL)
E3 ubiquitin ligase, that polyubiquitylates the HIF-a subunit, tar-
geting it for proteasomal degradation (Fig. 2). Under hypoxia,
PHD activity is reduced leading to stable HIF-a subunit
expression and binding to its regulatory elements [17] through
its N-terminal and C-terminal transactivation domains. HIFs
associate with the CREB binding protein (CBP) to form a
transcriptional activator complex. During extended periods of
low oxygen, as observed during pathological conditions, a HIF-1a
dependent feedback loop increases PHD expression, leading to a
reactivation of HIF-1a hydroxylation and degradation [19]. Thus,
HIF-1a expression can represent an acute response to low pO2,
whereas HIF-2a levels may increase over time in hypoxia and
play a role during chronic hypoxia [20].
It is important to consider another oxygen-sensitive
hydroxylase, factor inhibiting HIF (FIH), which regulates HIF-1a1398 Journal of Hepatology 2014expression. FIH hydroxylates an asparaginyl residue in the C-ter-
minal transactivation domain of HIF-1a (N803 in humans), but
not HIF-2a, inhibiting the binding of the heterodimer HIF-1 a
to its transcriptional coactivator p300 [21]. Although PHDs have
a reported low afﬁnity for oxygen (apparent Km in vitro of 230–
250 lM – a little over 21% O2), the Km of FIH is 90 lM (8%)
[22,23]. This has signiﬁcant implications for the signature of
genes transactivated by hypoxia, as FIH limits the activity of
the C-terminal transactivation domain of HIF-1a but not the N-
terminal domain [24]. In this way, cells can exhibit a biphasic
HIF-1a-dependent transcriptional proﬁle: a PHD-inactivation
dependent proﬁle under moderate hypoxia, and a PHD and FIH-
inactivation dependent proﬁle under more severe hypoxia.Oxygen-independent regulation of HIFs
A variety of oxygen-independent signalling events and cellular
stress can stabilize HIFa subunits in the presence of oxygen – a
phenotype known as ‘pseudohypoxia’ (Fig. 3). Cell surface recep-
tors, such as G protein-coupled receptors and receptor tyrosine
kinases promote HIF-1a mRNA translation and transactivational
activity. In the phosphatidylinositol-3-kinase (PI3K) pathway,
binding of a growth factor (e.g., insulin-like growth factor 1) tovol. 61 j 1397–1406
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Fig. 2. Oxygen dependent HIF signalling. Under normal oxygen tension (normoxia), the cellular oxygen sensors prolyl hydroxylases (PHD1–3) and factor inhibiting HIF
(FIH) hydroxylate speciﬁc residues of HIFa subunits (HIF-1a and 2a for PHDs and HIF-1a for FIH). Hydroxylated HIFa is recognized by the von Hippel-Lindau (pVHL) E3
ubiquitin ligase that polyubiquitinates HIFa resulting in proteasomal degradation. Under low oxygen (hypoxia) PHD and FIH activity is inhibited resulting in stable HIFa
expression and nuclear translocation where it dimerizes with its beta subunit. With the help of co-activators, including Cbp/p300, the HIF complex acts a transcription
factor by binding to speciﬁc DNA sequences deﬁned as hypoxia responsive elements (HREs), activating the transcription of genes involved in an array of signalling events
including tumour metastasis, cell survival, metabolism and immune functions. The HIFa signalling pathway is self-regulatory, nuclear HIF-1a promotes PHD expression
resulting in a negative feedback loop that ensures the pathway is not constitutively active.
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Fig. 3. Oxygen independent HIF signalling. HIFa can be constitutively expressed irrespective of oxygen tension due to loss of PHD and FIH function, a state deﬁned as
pseudohypoxia. This can occur as a result of virus infection or aberrant kinase signalling. For example, binding of a growth factor to its cognate receptor activates the MAPK
pathway that stabilizes HIFa. Similarly mitochondrial dysfunction can promote reactive oxygen species (ROS) production that acts on MAPK to stabilize HIFa. Hepatitis B
and C viruses stabilize HIF-1a under normoxia via an unknown mechanism.
JOURNAL OF HEPATOLOGYits cognate receptor activates PI3K that stimulates the down-
stream serine/threonine kinase Akt and the mechanistic target
of rapamycin (mTOR), providing a link between the microenvi-
ronment and HIF signalling, since mTOR activity is dependent
on the local concentration of amino acids. In addition, growth fac-Journal of Hepatology 2014tors can activate ERK and p70S6K1, an essential factor required
for HIF-1a mRNA translation. In addition to activating p70S6K1,
ERK can stimulate MAPK-interacting protein that activates the
translation initiator factor elF4E together with mTOR by
inhibiting the 4E-binding protein (4E-BP) (reviewed in [25,26]).vol. 61 j 1397–1406 1399
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Changes in nutrient availability can directly affect the levels
of HIFa proteins. Since both PHDs and FIH are dependent on
a-ketoglutarate for their activity, conditions that result in low
concentrations of this 2-oxo acid are likely to increase HIF
transcriptional activity. Finally, mitochondrial dysfunction
through the production of reactive oxygen species (ROS) from
the electron transport chain can stabilize HIFa subunits by
inactivating PHD enzymatic activity [27]. ROS levels are increased
during inﬂammation through various mechanisms, including the
activity of NADPH oxidase, as well as downstream of calcium
release in response to endoplasmic reticular stress [28–31].
The HIF system is regulated by a number of interconnected
signalling mechanisms in vivo. In pathological conditions affect-
ing the liver where HIFs are stabilized, the underlying mechanism
may alter with time, resulting in prolonged HIF-1a expression.
For example, during ischaemia, an acute reduction in blood ﬂow
stabilizes HIF-1 [32]. However, upon reperfusion, the inﬂux of
ROS can inactivate the PHDs [27], leading to oxygen-independent
HIF expression. This is followed by an increase in cellularity
through immune cell inﬁltration and vascular remodelling that
alters supply whilst increasing oxygen and nutrient demand,
allowing HIF signalling through yet another means. It is likely
that, at the lower end of the physiological gradient of oxygen in
the liver (i.e. 4% O2), small variations in tissue pO2 or non-
hypoxic pathways to regulate HIFs become highly signiﬁcant.
This review explores the impact of HIFs on hepatocellular biology
and immunity; highlighting how hypoxia or pseudohypoxia
induction of HIFs contributes to a wide range of liver pathologies
and may provide new therapeutic targets.HIFs in liver ischemia-reperfusion
Ischemia-reperfusion (I/R) mediated injury of the liver occurs
during hepatic resection and organ preservation prior to trans-
plantation and is a major factor in graft dysfunction [33]. During
ischemia, loss of oxygen and nutrients lead to a precipitous drop
in adenosine triphosphate levels that lead to a loss of membrane
function and metabolic dysfunction. However, the cellular dam-
age that occurs following restoration of the blood supply (reper-
fusion) via ROS-mediated oxidation of cellular proteins and lipids
can have signiﬁcant functional deﬁcits, if not cell death. Although
perfusion of the liver with completely anoxic ﬂuid results in uni-
form ischemia throughout the lobule, ischemia due to reduced
ﬂow was heterogeneous with the pericentral liver showing signs
of ischemic metabolic responses whilst the remaining liver was
unperturbed [34]. Evidence from a number of organ studies sug-
gest that HIFs play an important role in protecting the liver from
I/R injury [35–37]. HIF activation lies downstream of a number of
well-described protective pathways, including adenosine, nitric
oxide and AKT signalling [35,38], and its activity supports oxy-
gen-independent ATP generation as well as upregulation of ‘cell
preservation systems’, such as anti-oxidant and anti-apoptotic
proteins that allow for cell survival during and directly post
ischemia.HIFs and fatty liver disease
Fatty liver disease or hepatic steatosis, the excessive accumulation
of macro- or microvesicular cytoplasmic lipid droplets in1400 Journal of Hepatology 2014hepatocytes, is a major health concern due to its contribution to
obesity, type 2 diabetes and cardiovascular disease (reviewed in
[39]). Clinically it is categorized into alcoholic fatty liver disease
(AFLD) and non-alcoholic fatty liver disease (NAFLD) both ofwhich
can lead to ﬁbrosis, cirrhosis andHCC [40]. Several reports demon-
strate that rats fed a continuous ethanol diet show liver hypoxia
[8,41,42], although the direct contribution of HIF-1 to alcoholic
liver injury is unknown. Studies with rat hepatocytes show
enhanced de novo lipogenesis in perivenular cells, coupled with
increased esteriﬁcation of exogenous fatty acids into cellular and
very low density lipoprotein lipids [43], indirectly supporting a
role for low oxygen to regulate hepatic lipidmetabolism. The liter-
ature supports a role for HIFs to regulate hepatic lipogenesis
[3,44,45] and recent investigations have sought to deﬁne the rela-
tive contributions of HIF-1 and 2a.
The role of HIF-1a in steatohepatitis is the subject of conﬂicting
reports. Hepatocyte speciﬁc Hif1a knockout mice fed an ethanol
diet showed increased triglyceride and lipid accumulation via
inhibiting the Hif-1a target gene, differentiated embryo chondro-
cyte gene 1, (Dec1). Overexpression of Dec1 reversed the effects of
alcohol on liver biology, supporting a positive regulatory role for
Hif-1a regulated genes in protecting mice from AFLD [46].
However, Nath and colleagues reported that activating Hif1a in a
cre-lox mouse model induced hepatocyte steatosis and increased
triglyceride levels with ethanol feeding, whereas Hif1a deletion
prevented ethanol-induced lipid accumulation [9]. The reasons
for the disparity between these studies are not clear and may
reﬂect differences in the murine models used; however, the ﬁnd-
ings of Nath et al. are in line with recent data showing that Hif2
knockout adult mice develop steatosis [47]. In contrast, Kim and
colleagues reported that activating Hif1a or Hif2a in the murine
liver had a minimal effect on lipid accumulation. Activating both
Hif1a and Hif2a promoted macrovesicular lipid accumulation
[48], however, the relationship of this phenotype to human
diseases characterized by steatosis remains to be elucidated.
Genetic inactivation of Vhl/Hif1a in transgenic mice, which
results in HIF-2a speciﬁc responses, induced steatohepatitis with
impaired fatty acid b-oxidation and increased lipid droplets in
hepatocytes. Importantly, Hif2a inactivation decreased steatohep-
atitis. These data highlight a potential role for HIF-2a to deregu-
late hepatic lipid homeostasis [49]. Indeed, Vhl disruption in
mice augmented hepatic lipid accumulation in a HIF-2a depen-
dent manner and genome array studies demonstrate increased
transcription of genes associated with fatty acid synthesis and
uptake [11]. These studies highlight HIF-2a as a potential
therapeutic target for treating steatohepatitis. However, HIF-2a
perturbation of hepatic lipogenesis is intertwined with improved
insulin signalling in liver speciﬁc Phd3 knockoutmice, that exhibit
stable hepatic HIF-2a [50]. These observations were corroborated
byWei and colleagues who reported a link between Hif-2a expres-
sion in murine liver and increased hepatic insulin sensitivity via
induction of insulin receptor substrate 2 [51]. In addition, the
authors showed improved glucose tolerance and insulin signalling
in diabetic and non-diabetic mice following treatment with vas-
cular endothelial growth factor (VEGF) inhibitors. VEGF inhibition
induced local hypoxia by limiting sinusoidal vascularization
resulting in HIF-2a expression [51]. Taken together, these data
highlight the multiple roles HIF-2a plays in the liver,
where expression can both ameliorate diabetes and potentiate
dyslipidaemia. Further studies are required to deﬁne the mecha-
nisms by which HIFs modulate hepatic lipid homeostasis.vol. 61 j 1397–1406
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HIFs and inﬂammation
Chronic hepatitis of diverse aetiologies is characterized by
immune cell inﬁltration that promotes liver damage, however,
the impact of varying oxygen levels across the liver parenchyma
on immune cell function is not known. Inﬂammation is well
recognised to induce a shift in metabolic supply-and-demand
ratios that lead to localized tissue hypoxia, inducing cell-type
dependent HIF-transcriptional activities that regulate pro-inﬂam-
matory and anti-inﬂammatory responses [52]. A recent study
demonstrated that HIF-1a upregulates TLR4 expression in macro-
phages, suggesting that hypoxic stress at inﬂammatory sites
enhances innate cellular responses to bacterial pathogens [53].
Hypoxic macrophages show increased expression of IFN-gamma
[54], MHC-II and co-stimulatory molecules that may promote
antigen presenting capacity and immune synapse formation lead-
ing to increased T cell cytokine production [55]. A study of mye-
loid-speciﬁc Hif1 knockout mice reported an essential role for
HIF-1 in dendritic cells that deﬁned interferon and T cell activa-
tion [56]. Larbi et al. reported altered CD3/CD28-dependent T cell
proliferation and a switch in the respiratory pathway toward gly-
colysis at low oxygen tensions, suggesting that activation thresh-
olds, proliferation and susceptibility to apoptosis will differ under
varying oxygen levels [57]. Two recent reports highlight a posi-
tive regulatory role for hypoxia to induce FOXP3 expression in
human and murine mononuclear cells, leading to an increased
frequency and potency of regulatory T cells (Tregs) to suppress
effector cell proliferation [58,59]. This observation is consistent
with reports showing that interleukin-8 producing FOXP3+CD4+
regulatory T cells are enriched in the liver of subjects with
chronic HCV and HBV infection [60–62]. Collectively, these stud-
ies highlight the multi-factorial role for HIFs to link the innate
and adaptive immune systems and illustrate how hypoxia-
dependent changes in metabolic signals can induce an anti-
inﬂammatory program, providing new therapeutic opportunities
for the treatment of chronic liver inﬂammation.
Liver ﬁbrosis is characterised by the excessive deposition of
extracellular matrix (ECM) proteins such as type I collagen in
the liver parenchyma, representing a wound-healing response
to persistent or repeated injury [63]. Modiﬁcation of the paren-
chymal vasculature can promote regions of hypoxia; of note the
pattern of ﬁbrosis varies according to the underlying disease.
HIF-1a expression can activate hepatic stellate cells (HSCs) and
ﬁbroblasts to differentiate into myoﬁbroblasts that proliferate
and migrate to injured areas where they secrete ECM [64–67].
In vivo studies using bile duct ligated mice, an animal model of
liver ﬁbrosis, show increased Hif-1a expression 3 days after sur-
gery whereas Hif1a-deﬁcient ligated mice show a signiﬁcant
reduction in ﬁbrogenic mediators [66].
Macrophages are recruited to the liver following injury to
sites of inﬂammation where they secrete transforming growth
factor-beta (TGF-b) and platelet derived growth factor (PDGF)
that can activate HSCs and promote ﬁbrogenesis [68,69]. Nuclear
HIF-1awas detected in macrophages, ﬁbroblasts and hepatocytes
in liver biopsies collected from subjects with primary biliary cir-
rhosis and primary sclerosing cholangitis [70]. Together, these
data support a potential role for macrophage expressed HIFs in
the development of hepatic ﬁbrosis, however, the acquisition of
a hypoxic phenotype by macrophages in the context of ﬁbrosis
is unknown. A potential positive role for HIF-2a in liver ﬁbrosis
was supported by experimental studies in genetically manipu-Journal of Hepatology 2014lated mice, where liver speciﬁc disruption of Vhl enhanced the
transcription of pro-ﬁbrogenic genes in a HIF-2a dependent man-
ner, as conﬁrmed by whole genome microarray analysis. In con-
trast, pro-ﬁbrogenic gene expression was signiﬁcantly reduced in
mice carrying a Hif2a speciﬁc deletion [11]. Taken together, these
data suggest complementary roles for HIFs in liver ﬁbrosis.HIFs and viral hepatitis
It is interesting to note that both hepatitis B and C viruses stabi-
lize HIF-1a and promote a pseudohypoxic state. Despite their dif-
ferent replication strategies, both viruses have developed
successful ways to establish chronic infection, resulting in 350
and 180 million infected subjects worldwide, respectively [71].
Infection by either virus leads to serious and progressive liver dis-
ease, including steatosis, ﬁbrosis, cirrhosis and HCC. HBV encoded
protein X (HBx) is a multifunctional protein with transcriptional
activity via its interaction with nuclear transcription factors and
modulation of cytoplasmic signal transduction pathways, such
as RAS/RAF/MAP signalling [72]. Transgenic mice expressing the
HBx gene develop hepatic pathological changes including adeno-
mas and malignant carcinomas [73]. In vitro studies suggest that
oncogenicity of HBx is mediated via HIF-1a expression, resulting
in enhanced cell invasion and proliferation [74,75]. A recent
study demonstrated that mutations commonly found in the
HBx gene enhanced HIF-1a expression and transcriptional activ-
ity [76], suggesting differences between infecting viral genotypes
that may predict HCC tumour pathogenesis. Although a growing
body of evidence suggests that HBx stabilizes HIF-1a, the major-
ity of studies have been performed with ectopic protein expres-
sion as opposed to infectious virus, reﬂecting the limited
infectivity of full-length HBV genomes in vitro. Nevertheless,
investigating HBx activity in the context of an infected cell is a
worthwhile endeavour and highlights the need to develop robust
culture models to propagate HBV in vitro.
Studies with HCV demonstrate a virus-induced pseudohypox-
ic response [10,77,78], showing stable HIF-1a expression under
normoxic conditions. Furthermore, hypoxia promotes HCV repli-
cation, while inhibiting HIF-1a activity reduced viral replication
[12,79]. Current understanding of the role that HIF-1a plays in
the HCV lifecycle is limited. However, one may hypothesize that
HIF-dependent changes in hepatocyte permeability and metabo-
lism favours viral transmission and replication, respectively. We
previously reported that hepatocyte polarity restricts HCV entry
in vitro and the virus overcomes this barrier by promoting HIF-
dependent transcriptional activation of VEGF that depolarizes
hepatocytes and aids viral dissemination [80,81]. VEGF is a
well-characterized HIF-1a regulated gene that plays an essential
role in angiogenesis and HCV infection, and is associated with
elevated neoangiogenesis [77], suggesting a key role for HIF-reg-
ulated genes in potentiating the virus lifecycle [12,80].
The development of high-throughput metabolomics has pro-
vided new insights into how viruses modulate host metabolism
[82,83]. Metabolic proﬁling of HCV infected cells revealed a shift
from an energy consuming to energy conserving phenotype, pro-
moting the survival of infected cells [84]. Given the role of HIF-
1a in regulating glucose metabolism, HCV stabilization of HIF-1a
may have a positive effect on virus replication via the induction
of a transformed metabolic phenotype. Ripoli et al., investigated
the effect of constitutive HIF-1a activity on hepatocyte metabo-
lism during HCV infection [78], reporting a reduction invol. 61 j 1397–1406 1401
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mitochondrial oxidative phosphorylation and increased glycolytic
enzyme expression. These ﬁndings highlight a metabolic shift that
is reminiscent of aerobic glycolysis and provides insights into the
effect of viral infection on host bioenergetics. Moreover, these
observations suggest that HIF-1a-dependent cellular reprogram-
ming may promote HCV-associated HCC pathogenesis.HIFs and hepatocellular carcinoma
HCC is the most common primary liver malignancy, with an esti-
mated 750,000 new cases and 695,000 deaths per year, rating
third in incidence and mortality in the world. The major risk fac-
tor for HCC is chronic liver disease with a high frequency of hep-
atitis B and C infections [85]. Whilst incidence and mortality for
other cancers is declining, this tumour represents an increasing
signiﬁcant public health problem. Despite advances in HCC treat-
ment, most patients die within one year of diagnosis largely due
to recurrence and metastases. Hypoxia is a prominent feature of
solid tumours as a result of their defective vascularization and
intense metabolic activity, associating with poor prognosis and
resistance to chemotherapeutic agents/radiation [86]. HIF medi-
ates expression of genes involved in every step of HCC metastasis
including EMT [87], invasion of the extracellular matrix, intrava-
sation, extravasation and secondary growth of metastases. HIF-
1a expression in HCC is a negative prognostic factor for clinical
outcome after surgery [88] and is associated with metastatic
potential [89,90]. The impact of HBV and HCV stabilization of
HIFs in HCC pathogenesis is not known.
Solid tumours showing high levels of glycolysis and hypoxia-
mediated transcriptional responses reinforce and strengthen the
glycolytic phenotype by upregulating almost every enzyme in
this pathway, including hexokinase 2 (HK2) and lactate dehydro-
genase A (LDHA). Glycolysis has been reported to fuel hypoxic
solid tumours such as hepatocellular carcinoma (HCC), where
increased HK2 expression stimulates the proliferation of malig-
nant cells. Moreover, inhibiting HK2 expression in a murine
HCC model increased tumour cell apoptosis and limited tumour
growth [91,92]. The production of lactate from pyruvate is regu-
lated by LDHA and its knockdown has been shown to suppress
tumour growth and metastasis in vivo and in vitro [93]. Together
these reports suggest a role for glucose metabolism in HCC
metastasis and HIF-1a signalling is likely to play an essential role.
Indeed, HIF-1a stabilization may be one of the drivers of aerobic
glycolysis, a phenotype observed in many tumour types [94].
Ma and colleagues demonstrated reduced gluconeogenesis in
malignant hepatocytes in a murine HCC tumour model and
showed that restoring gluconeogenesis with a synthetic steroid
inhibited hepatocellular tumour growth [95]. Since HIF-2a
expression has been reported to reduce hepatic gluconeogenesis
[96], it is tempting to speculate a positive regulatory role for HIF-
2a in HCC pathogenesis. However, recent data showing that over-
expression of HIF-2a in murine HCC models inhibits tumour
growth, highlight the need for further studies to address the role
of this transcription factor in HCC metastasis [97].HIFs and HCC microenvironment
The HCC microenvironment comprises tumour cells within the
extracellular matrix and stromal cells that include: angiogenic
cells, immune cells and cancer associated ﬁbroblastic cells (CAFs).1402 Journal of Hepatology 2014There is a growing body of evidence on the role stromal cells play
in deﬁning cancer progression and response to therapies, partic-
ularly in breast, lung and pancreatic carcinomas [98]. Alterations
within the microenvironment, in particular in stromal ﬁbroblasts,
may inﬂuence tumour initiation in adjacent epithelia and pro-
mote progression. Moreover, the microenvironment plays an
important role in chemoresistance [99,100] and drug delivery
[101]. Targeting stromal cells to abrogate their tumour-support-
ing role represents an attractive therapeutic strategy. However,
our current understanding of how stromal cells respond to low
oxygen and the various paracrine pathways that are elicited to
promote HCC growth are poorly deﬁned [102]. CAFs represent
one of the most dominant cell types in most tumours, however,
there are limited studies on this cell type in HCC. Lin et al.
reported that two human CAF cell lines promote HCC by upregu-
lating the expression of cytokines and growth factors (APLN, CCL2,
CCL26, CXCR4, IL6, MUC1, LOXL2, PDGFA, PGK1, VEGFA) related to
proliferation, migration, invasion and angiogenesis [103]. A
recent study showed that HCC-derived tumour cells secrete lyso-
phosphatidic acid (LPA) that activates peritumuoral ﬁbroblasts to
adopt a CAF phenotype and accelerates HCC progression [104].
The authors demonstrated that inhibiting LPA blocked the trans-
differentiation of myoﬁbroblasts and tumour progression in mur-
ine models, providing an exciting new therapeutic target. Given a
number of reports showing that LPA activates PI3K and stabilizes
HIF-1a in adipocytes [105], colon tumour cells [106] and PC3
prostate cancer cells [107], it is tempting to speculate a HIF-1a
dependent pathway in HCC.
HCC is frequently associated with large numbers of lympho-
cytes, including tumour-speciﬁc CD8 cells, regulatory T cells,
NKT and NK cells. Several immunoregulatory mechanisms have
been implicated in the suppression of anti-tumour immunity,
including expression of pro-apoptotic molecules such as PD-1
on tumour cells, recruitment of regulatory T cells, immunosup-
pressive myeloid derived cells (MDSCs) and inactivation of NK
responses by soluble NKG2D ligands (MICA/B) [59,108,109]. PD-
1 ligand was recently reported to be a direct target of HIF-1a
[110], suggesting that the simultaneous blockade of PD-L1 and
HIF-1a may represent a novel approach to treat HCC. Doedens
et al. recently reported that HIFs inﬂuence the expression of tran-
scription, effector and costimulatory-inhibitory molecules of viral
speciﬁc cytotoxic T cells, highlighting new strategies to promote
the clearance of viruses and tumours [111]. Thus, HIF-1a can
exert direct effects on tumour and vascular cells that prime selec-
tive chemokine-mediated recruitment of suppressive and pro-
angiogenic T-cell subsets. Our current understanding of how hyp-
oxic conditions affect innate immune cells and their role in HCC
tumourigenesis is poorly understood and further research is
required to increase our understanding of the role HIFs plays in
anti-HCC immunity [112].HIFs and HCC treatment
HCC has dual causes of morbidity and mortality, namely the can-
cer and the underlying chronic liver disease. The majority of
patients present with disease too advanced for surgical resection
and require liver transplantation. A small percentage of patients
are suitable for trans-arterial chemoembolisation, a procedure
that exploits the vascularity of HCC tumour nodules, whilst this
may provide a modest increase in survival, the disease progresses
and treatment-associated hypoxia promotes revascularisation,vol. 61 j 1397–1406
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invasion and metastasis [113]. Anti-angiogenic agents that target
HIF-regulated VEGF are used as ﬁrst and second line treatments
for several cancers, including HCC. The kinase inhibitors sorafenib
and sunitinib that target VEGF receptors have been approved for
the treatment of HCC and gastrointestinal stromal tumours,
respectively. Recent randomised phase 3 placebo-controlled tri-
als demonstrate a survival advantage for the multi-targeted
kinase inhibitor sorafenib in patients with advanced HCC [114].
However, the effects are modest with a median improvement
in overall survival of 2 to 3 months with no clinical or molecular
biomarkers to identify patients most likely to beneﬁt. A number
of randomised trials of other VEGF-targeted drugs (including sun-
itinib and brivanib) have failed to demonstrate any further sur-
vival beneﬁt in either the ﬁrst or second line setting and most
patients die within one year of diagnosis, largely due to further
metastases [115]. Therapy-induced tumour hypoxia has been
observed in response to diverse treatments, including radiother-
apy [116,117], chemotherapy [118,119], anti-angiogenic and vas-
cular disrupting agents [120]. Current data suggest that
resistance to VEGF inhibitors associates with a more invasive/
metastatic tumour phenotype and activation of HIF-dependent
angiogenic pathways.
The high failure rate of phase 3 trials for HCC is forcing the sci-
entiﬁc community to optimize trial design and to consider molec-
ular tumour proﬁling to select patients most likely to respond to
therapy [121]. The search for molecular predictors of response is
becoming standard practice in clinical oncology research and
relies on the concept of ‘oncogenic addiction’ that is based on a
priori knowledge of the speciﬁc molecular alterations for tumour
progression on an individual basis [122]. Unlike other solid
tumours (e.g., lung, colon or breast) there is limited information
on oncogenic addiction loops in HCC. Considerable research
efforts have focused on the molecular proﬁling of HCC tumours
with the goal of identifying gene signatures that predict disease
outcome following treatment [123–126]. To date, there has been
limited concordance between studies, that may reﬂect HCC
tumour heterogeneity [127]. Van Malenstein et al. reported a
seven-gene hypoxic gene signature that correlated with poor
prognosis in HCCs, however, the authors deﬁned hypoxic tumour
gene signatures by comparing mRNA proﬁles to an in vitro control
sample where HepG2 hepatoblastoma cells were propagated
under 2% oxygen for 72 h. From our experience, HIF expression
and transcriptional activity is optimal between 24 and 48 h
post-hypoxic treatment and declines signiﬁcantly by 72 h, limit-
ing the conclusions of this study. More recently, Nault et al.
reported a HCC ﬁve-gene score, associated with patient survival
following liver resection in different clinical settings, including
the identiﬁcation of four new genes RAN, TAF9, RAMP3, and HN1
which reﬂect signalling pathways associated with HCC prognosis.
It will be interesting to see whether any of these genes are trans-
criptionally regulated by HIFs and how this new biomarker will
perform in the clinical setting to stratify patients for therapy.HIF as a therapeutic target
Several in vivo studies highlight the value of targeting the HIF
pathway to inhibit tumour progression [128] and to improve
the efﬁcacy of VEGF-targeted therapies by modulating the hyp-
oxic tumour microenvironment. Targeting HIFs can limit the
unwanted effects of therapy-induced tumour hypoxia observed
with c-radiation [116,129] and anti-angiogenic agents, resultingJournal of Hepatology 2014in signiﬁcantly improved treatment efﬁcacy in pre-clinical mod-
els [120]. A number of pharmacological agents that target HIF
either directly or indirectly are in pre-clinical studies or clinical
trials, mostly as novel means of treating advanced cancers
[118,130]. The HIF-1a antagonist EZN-2968 is a locked nucleic
acid antisense oligonucleotide that speciﬁcally downregulates
HIF-1amRNA and protein expression. In vivo studies show a spe-
ciﬁc and long-lasting down-modulation of HIF-1a and VEGF in
the liver of mice and anti-tumour effects on human xenografts
[131]. We previously reported that inducing PHD enzyme activity
with derivatives of alpha-ketoglutarate represent a novel method
to target hypoxic areas of tumours [132,133]. Unlike therapies
that differentiate between HIF isoforms, this would reduce sig-
nalling through both HIF-1a and 2a, which may be more tumou-
ricidal than approaches that only target one. Agents that inhibit
reactive oxygen species generation, such as superoxide dismutase
mimetics, have also been shown to decrease HIF levels [134].
Other less direct mechanisms of reducing HIF-1 transcriptional
activity include the use of mTOR inhibitors such as the rapalogs,
inhibitors of AKT activity or dual speciﬁcity mTOR/PI3K inhibitors
like NVP-BEZ235 [135] that target other important signalling
pathways in parallel with the HIF axis. These studies highlight
the therapeutic potential of targeting HIFs for the treatment of
HCC, however, our review of the currently available literature
suggests that targeting HIFs may improve an array of liver pathol-
ogies including steatohepatitis and viral hepatitis.Concluding remarks
Recent studies highlight a role for HIFs in the pathogenesis of
chronic liver disease and HCC. Much of our current understand-
ing is based on murine models and it will be important to trans-
late these observations into man and to develop in vitro culture
systems that incorporate hepatic oxygen levels: enabling studies
to characterize the impact of oxygen tension on liver resident and
inﬁltrating immune cell function ex vivo. It is interesting to note
that both HBV and HCV induce a pseudohypoxic cellular pheno-
type. However, this observation is not unique to these hepatotro-
pic viruses, with a number of other viruses including Epstein-Barr
virus and Cytomegalovirus inducing a cellular hypoxic response
[136,137]. Viral hijacking of the HIF-pathway is likely to provide
signiﬁcant beneﬁts to many steps in the viral life cycle, however,
it may also provide a novel therapeutic target to limit viral repli-
cation and associated pathologies.Conﬂict of interest
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